Department of Justice
Drug Enforcement Administration
By Notice dated January 26, 2012, and published in the Federal Register on February 6, 2012, 77 FR 5847, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:
The company plans to manufacture reference standards.
No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research Biochemicals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.
21 U.S.C. 823(a)
21 CFR 1301.33| Drug | Schedule |
|---|---|
| Cathinone (1235) | I |
| Methcathinone (1237) | I |
| 4-methyl-N-methylcathinone (1248) | I |
| Aminorex (1585) | I |
| Alpha-ethyltryptamine (7249) | I |
| Lysergic acid diethylamide (7315) | I |
| 3,4-methylenedioxypyrovalerone (7535) | I |
| 3,4-methylenedioxy-N-methylcathinone (7540) | I |
| Tetrahydrocannabinols (7370) | I |
| 4-Bromo-2,5-dimethoxyamphetamine (7391) | I |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392) | I |
| 2,5-Dimethoxyamphetamine (7396) | I |
| 3,4-Methylenedioxyamphetamine (7400) | I |
| N-Hydroxy-3,4-methylenedioxyamphetamine (7402) | I |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404) | I |
| 3,4-Methylenedioxymethamphetamine (7405) | I |
| Psilocybin (7437) | I |
| ( printed page 31391) | |
| 5-Methoxy-N,N-diisopropyltryptamine (7439) | I |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) | I |
| N-Benzylpiperazine (7493) | I |
| Heroin (9200) | I |
| Normorphine (9313) | I |
| Amphetamine (1100) | II |
| Methamphetamine (1105) | II |
| Nabilone (7379) | II |
| 1-Phenylcyclohexylamine (7460) | II |
| Phencyclidine (7471) | II |
| Cocaine (9041) | II |
| Codeine (9050) | II |
| Diprenorphine (9058) | II |
| Ecgonine (9180) | II |
| Levomethorphan (9210) | II |
| Levorphanol (9220) | II |
| Meperidine (9230) | II |
| Metazocine (9240) | II |
| Methadone (9250) | II |
| Morphine (9300) | II |
| Thebaine (9333) | II |
| Levo-alphacetylmethadol (9648) | II |
| Remifentanil (9739) | II |
| Sufentanil (9740) | II |
| Carfentanil (9743) | II |
| Fentanyl (9801) | II |
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.